Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):770–779. doi: 10.1038/sj.bjc.6690124

Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder

M Milella 1, J Jacobelli 1, F Cavallo 2, A Guarini 3, F Velotti 4, L Frati 1, R Foà 3, G Forni 2, A Santoni 1
PMCID: PMC2362658  PMID: 10070868

Abstract

Transitional cell carcinoma of the bladder is one of the human cancers most responsive to immunotherapy, and local interleukin-2 (IL-2) production appears to be an important requirement for immunotherapy to be effective. In this study, we engineered two human bladder cancer cell lines (RT112 and EJ) to constitutively release human IL-2 by retroviral vector-mediated gene transfer. Following infection and selection, stable and consistent production of biologically active IL-2 was demonstrated at both the mRNA and the protein level. Morphology, in vitro growth rate and proliferation, as well as other cytokine gene mRNA or membrane adhesion receptor expression, were not altered in IL-2 transduced cells as compared to their parental or control vector-infected counterparts. Moreover, IL-2 engineered cells lost their tumorigenicity into nu/nu mice and the mechanism of rejection appeared to involve multiple host effector cell populations, among which a prominent role was played by neutrophils and radiosensitive cells. These findings may offer support to the development of an IL-2-based gene therapy approach to human bladder cancer. 1999 Cancer Research Campaign

Keywords: human, interleukin-2, transitional bladder cancer, gene therapy, immunotherapy

Full Text

The Full Text of this article is available as a PDF (978.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alosco T., Croy B. A., Gansbacher B., Wang H. Q., Rao U., Bankert R. Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells. Cancer Immunol Immunother. 1993 Jun;36(6):364–372. doi: 10.1007/BF01742252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bass C., Cabrera G., Elgavish A., Robert B., Siegal G. P., Anderson S. C., Maneval D. C., Curiel D. T. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther. 1995 Jun;2(2):97–104. [PubMed] [Google Scholar]
  3. Cavallo F., Giovarelli M., Gulino A., Vacca A., Stoppacciaro A., Modesti A., Forni G. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol. 1992 Dec 1;149(11):3627–3635. [PubMed] [Google Scholar]
  4. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  5. Cignetti A., Guarini A., Carbone A., Forni M., Cronin K., Forni G., Gansbacher B., Foa R. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J Natl Cancer Inst. 1994 May 18;86(10):785–791. doi: 10.1093/jnci/86.10.785. [DOI] [PubMed] [Google Scholar]
  6. Colombo M. P., Modesti A., Parmiani G., Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 1992 Sep 15;52(18):4853–4857. [PubMed] [Google Scholar]
  7. Connor J., Bannerji R., Saito S., Heston W., Fair W., Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med. 1993 Apr 1;177(4):1127–1134. doi: 10.1084/jem.177.4.1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Djeu J. Y., Liu J. H., Wei S., Rui H., Pearson C. A., Leonard W. J., Blanchard D. K. Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2. J Immunol. 1993 Feb 1;150(3):960–970. [PubMed] [Google Scholar]
  9. Dranoff G., Mulligan R. C. Gene transfer as cancer therapy. Adv Immunol. 1995;58:417–454. doi: 10.1016/s0065-2776(08)60624-0. [DOI] [PubMed] [Google Scholar]
  10. Fearon E. R., Pardoll D. M., Itaya T., Golumbek P., Levitsky H. I., Simons J. W., Karasuyama H., Vogelstein B., Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990 Feb 9;60(3):397–403. doi: 10.1016/0092-8674(90)90591-2. [DOI] [PubMed] [Google Scholar]
  11. Forni G., Cavallo G. P., Giovarelli M., Benetton G., Jemma C., Barioglio M. G., De Stefani A., Forni M., Santoni A., Modesti A. Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Experimental and clinical results. Prog Exp Tumor Res. 1988;32:187–212. doi: 10.1159/000414679. [DOI] [PubMed] [Google Scholar]
  12. Gansbacher B., Zier K., Cronin K., Hantzopoulos P. A., Bouchard B., Houghton A., Gilboa E., Golde D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood. 1992 Dec 1;80(11):2817–2825. [PubMed] [Google Scholar]
  13. Gastl G., Finstad C. L., Guarini A., Bosl G., Gilboa E., Bander N. H., Gansbacher B. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 1992 Nov 15;52(22):6229–6236. [PubMed] [Google Scholar]
  14. Girard D., Gosselin J., Heitz D., Paquin R., Beaulieu A. D. Effects of interleukin-2 on gene expression in human neutrophils. Blood. 1995 Aug 1;86(3):1170–1176. [PubMed] [Google Scholar]
  15. Guarini A., Gansbacher B., Cronin K., Fierro M. T., Foa R. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response. Cytokines Mol Ther. 1995 Mar;1(1):57–64. [PubMed] [Google Scholar]
  16. Guarini A., Riera L., Cignetti A., Montacchini L., Massaia M., Foa R. Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood. 1997 Jan 1;89(1):212–218. [PubMed] [Google Scholar]
  17. Hara I., Nguyen H., Takechi Y., Gansbacher B., Chapman P. B., Houghton A. N. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer. 1995 Apr 10;61(2):253–260. doi: 10.1002/ijc.2910610219. [DOI] [PubMed] [Google Scholar]
  18. Hathorn R. W., Tso C. L., Kaboo R., Pang S., Figlin R., Sawyers C., deKernion J. B., Belldegrun A. In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. Cancer. 1994 Oct 1;74(7):1904–1911. doi: 10.1002/1097-0142(19941001)74:7<1904::aid-cncr2820740713>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  19. Hawkyard S. J., Jackson A. M., Prescott S., James K., Chisholm G. D. The effect of recombinant cytokines on bladder cancer cells in vitro. J Urol. 1993 Aug;150(2 Pt 1):514–518. doi: 10.1016/s0022-5347(17)35538-6. [DOI] [PubMed] [Google Scholar]
  20. Hicks C., Cooley M. A., Penny R. Investigation of interleukin 2 receptors on human endothelial cells. Growth Factors. 1991;5(3):201–208. doi: 10.3109/08977199109000284. [DOI] [PubMed] [Google Scholar]
  21. Liu J. H., Wei S., Ussery D., Epling-Burnette P. K., Leonard W. J., Djeu J. Y. Expression of interleukin-2 receptor gamma chain on human neutrophils. Blood. 1994 Dec 1;84(11):3870–3875. [PubMed] [Google Scholar]
  22. Masters J. R., Hepburn P. J., Walker L., Highman W. J., Trejdosiewicz L. K., Povey S., Parkar M., Hill B. T., Riddle P. R., Franks L. M. Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res. 1986 Jul;46(7):3630–3636. [PubMed] [Google Scholar]
  23. Meazza R., Marciano S., Sforzini S., Orengo A. M., Coppolecchia M., Musiani P., Ardizzoni A., Santi L., Azzarone B., Ferrini S. Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer. Br J Cancer. 1996 Sep;74(5):788–795. doi: 10.1038/bjc.1996.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Melani C., Chiodoni C., Arienti F., Maccalli C., Sule-Suso J., Anichini A., Colombo M. P., Parmiani G. Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. Nat Immun. 1994 Mar-Jun;13(2-3):76–84. [PubMed] [Google Scholar]
  25. Miller A. D., Rosman G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989 Oct;7(9):980-2, 984-6, 989-90. [PMC free article] [PubMed] [Google Scholar]
  26. Musiani P., Modesti A., Giovarelli M., Cavallo F., Colombo M. P., Lollini P. L., Forni G. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today. 1997 Jan;18(1):32–36. doi: 10.1016/s0167-5699(97)80012-6. [DOI] [PubMed] [Google Scholar]
  27. Nista A., Mattioni M., Gismondi A., Palmieri G., Santoni A. beta 1-Integrin expression and function in human bladder cancer cells: modulation by TNF alpha. Anticancer Res. 1996 Mar-Apr;16(2):581–588. [PubMed] [Google Scholar]
  28. Okamoto M., Hattori K., Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer. 1997 Jul 3;72(1):149–154. doi: 10.1002/(sici)1097-0215(19970703)72:1<149::aid-ijc21>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  29. Pericle F., Kirken R. A., Epling-Burnette P. K., Blanchard D. K., Djeu J. Y. Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int J Cancer. 1996 May 3;66(3):367–373. doi: 10.1002/(SICI)1097-0215(19960503)66:3<367::AID-IJC17>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  30. Sitkovsky M. V., Paul W. E. Immunology. Global or directed exocytosis? Nature. 1988 Mar 24;332(6162):306–307. doi: 10.1038/332306a0. [DOI] [PubMed] [Google Scholar]
  31. Stein U., Walther W., Shoemaker R. H. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst. 1996 Oct 2;88(19):1383–1392. doi: 10.1093/jnci/88.19.1383. [DOI] [PubMed] [Google Scholar]
  32. Tubaro A., Stoppacciaro A., Velotti F., Bossola P. C., Cusumano G., Vicentini C., De Carli P., Ruco L., Santoni A., Cancrini A. Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2. Eur Urol. 1995;28(4):297–303. doi: 10.1159/000475070. [DOI] [PubMed] [Google Scholar]
  33. Tubaro A., Velotti F., Stoppacciaro A., Santoni A., Vicentini C., Bossola P. C., Galassi P., Pettinato A., Morrone S., Napolitano T. Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer. A phase IB study. Cancer. 1991 Jul 1;68(1):56–61. doi: 10.1002/1097-0142(19910701)68:1<56::aid-cncr2820680111>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  34. Velotti F., Stoppacciaro A., Ruco L., Tubaro A., Pettinato A., Morrone S., Napolitano T., Bossola P. C., Franks C. R., Palmer P. Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2. Cancer Res. 1991 May 1;51(9):2456–2462. [PubMed] [Google Scholar]
  35. Verstovsek S., Maccubbin D., Ehrke M. J., Mihich E. Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha. Cancer Res. 1992 Jul 15;52(14):3880–3885. [PubMed] [Google Scholar]
  36. Wei S., Blanchard D. K., Liu J. H., Leonard W. J., Djeu J. Y. Activation of tumor necrosis factor-alpha production from human neutrophils by IL-2 via IL-2-R beta. J Immunol. 1993 Mar 1;150(5):1979–1987. [PubMed] [Google Scholar]
  37. Wei S., Liu J. H., Blanchard D. K., Djeu J. Y. Induction of IL-8 gene expression in human polymorphonuclear neutrophils by recombinant IL-2. J Immunol. 1994 Apr 1;152(7):3630–3636. [PubMed] [Google Scholar]
  38. Xu H. J., Zhou Y., Seigne J., Perng G. S., Mixon M., Zhang C., Li J., Benedict W. F., Hu S. X. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res. 1996 May 15;56(10):2245–2249. [PubMed] [Google Scholar]
  39. Yasumura S., Lin W. C., Weidmann E., Hebda P., Whiteside T. L. Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int J Cancer. 1994 Oct 15;59(2):225–234. doi: 10.1002/ijc.2910590215. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES